The
following table presents information about the Company’s reportable segments for the three months ended March 31, 2026 and 2025:
SCHEDULE OF INFORMATION RELATED TO OPERATIONS OF REPORTABLE OPERATING SEGMENTS
| | |
2026 | | |
2025 | |
| | |
Three months ended | |
| | |
March 31 | |
| | |
2026 | | |
2025 | |
| | |
| | |
| |
| Revenue from biotechnology activity | |
| - | | |
| - | |
| Cost related to biotechnology activity (*) | |
| (125 | ) | |
| - | |
| Salaries and related expenses related to biotechnology activity | |
| (256 | ) | |
| - | |
| Amortization of intangible asset | |
| (100 | ) | |
| - | |
| Operating loss from Biotechnology activity | |
| (481 | ) | |
| - | |
| | |
| | | |
| | |
| Revenue from renewable energy projects | |
| - | | |
| - | |
| Cost related to renewable energy projects | |
| (4 | ) | |
| (71 | ) |
| Operating loss from renewable energy projects | |
| (4 | ) | |
| (71 | ) |
| | |
| | | |
| | |
| Professional services | |
| (423 | ) | |
| (238 | ) |
| Share base compensation | |
| (1,149 | ) | |
| (41 | ) |
| Change in fair value of contingent consideration | |
| 343 | | |
| - | |
| Goodwill impairment | |
| (6,291 | ) | |
| - | |
| Depreciation | |
| (3 | ) | |
| - | |
| Other general and administrative expenses | |
| (217 | ) | |
| (153 | ) |
| Total Operating loss | |
| (8,225 | ) | |
| (503 | ) |
| | |
| | | |
| | |
| Interest of loans | |
| - | | |
| (77 | ) |
| Financing expenses, net | |
| (100 | ) | |
| (639 | ) |
| Other income | |
| 386 | | |
| - | |
| Changes in fair value of investments measured under the fair value option | |
| 492 | | |
| 103 | |
| Income taxes | |
| 23 | | |
| - | |
| Net loss | |
| (7,424 | ) | |
| (1,116 | ) |
| (*) | | Costs
related to biotechnology activity primarily consist of subcontractors engaged in research and development activities. |
|